Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 11.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 121,293 shares of the company’s stock after acquiring an additional 12,503 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Cardiff Oncology were worth $324,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of Cardiff Oncology in the second quarter worth approximately $256,000. Rhumbline Advisers purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $102,000. Ground Swell Capital LLC acquired a new stake in shares of Cardiff Oncology during the 2nd quarter worth $38,000. American Century Companies Inc. raised its position in shares of Cardiff Oncology by 98.7% in the 2nd quarter. American Century Companies Inc. now owns 45,360 shares of the company’s stock worth $101,000 after buying an additional 22,536 shares during the period. Finally, Thoroughbred Financial Services LLC acquired a new position in Cardiff Oncology in the second quarter valued at $116,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Insider Activity at Cardiff Oncology

In related news, Director Gary W. Pace purchased 350,115 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the acquisition, the director now directly owns 1,047,876 shares in the company, valued at $2,724,477.60. The trade was a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.60% of the company’s stock.

Cardiff Oncology Price Performance

Shares of CRDF opened at $4.49 on Friday. Cardiff Oncology, Inc. has a 12 month low of $1.37 and a 12 month high of $6.42. The stock’s 50-day moving average is $3.05 and its two-hundred day moving average is $2.66. The stock has a market cap of $229.59 million, a PE ratio of -4.78 and a beta of 1.89.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Craig Hallum began coverage on Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 price objective on the stock. Piper Sandler raised their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, HC Wainwright decreased their price objective on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, November 8th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.